Wealthfront Advisers’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13M | Sell |
25,833
-6,435
| -20% | -$3.09M | 0.02% | 222 |
|
|
2026
Q1 | $15.9M | Buy |
32,268
+4,145
| +15% | +$2.25M | 0.03% | 176 |
|
|
2025
Q4 | $16.3M | Buy |
28,123
+5,738
| +26% | +$3.24M | 0.04% | 163 |
|
|
2025
Q3 | $10.9M | Buy |
22,385
+6,954
| +45% | +$3.24M | 0.03% | 225 |
|
|
2025
Q2 | $6.26M | Sell |
15,431
-7,068
| -31% | -$2.96M | 0.02% | 328 |
|
|
2025
Q1 | $11.2M | Sell |
22,499
-26
| -0.1% | -$14.1K | 0.03% | 180 |
|
|
2024
Q4 | $11.7M | Buy |
22,525
+945
| +4% | +$520K | 0.03% | 159 |
|
|
2024
Q3 | $13.3M | Buy |
21,580
+346
| +2% | +$205K | 0.04% | 134 |
|
|
2024
Q2 | $11.7M | Buy |
21,234
+38
| +0.2% | +$21.8K | 0.04% | 133 |
|
|
2024
Q1 | $12.3M | Buy |
21,196
+1,374
| +7% | +$771K | 0.04% | 127 |
|
|
2023
Q4 | $10.5M | Sell |
19,822
-1,390
| -7% | -$673K | 0.04% | 131 |
|
|
2023
Q3 | $10.7M | Buy |
21,212
+817
| +4% | +$435K | 0.05% | 115 |
|
|
2023
Q2 | $10.6M | Sell |
20,395
-7,095
| -26% | -$3.83M | 0.05% | 120 |
|
|
2023
Q1 | $15.8M | Buy |
27,490
+835
| +3% | +$471K | 0.07% | 72 |
|
|
2022
Q4 | $14.7M | Sell |
26,655
-9,068
| -25% | -$4.81M | 0.07% | 75 |
|
|
2022
Q3 | $18.1M | Buy |
35,723
+1,522
| +4% | +$852K | 0.1% | 58 |
|
|
2022
Q2 | $18.6M | Sell |
34,201
-1,777
| -5% | -$978K | 0.09% | 59 |
|
|
2022
Q1 | $21.3M | Buy |
35,978
+711
| +2% | +$408K | 0.09% | 52 |
|
|
2021
Q4 | $23.5M | Buy |
35,267
+5,500
| +18% | +$3.43M | 0.1% | 45 |
|
|
2021
Q3 | $17M | Buy |
29,767
+7,690
| +35% | +$4.22M | 0.08% | 48 |
|
|
2021
Q2 | $11.1M | Buy |
22,077
+572
| +3% | +$270K | 0.05% | 64 |
|
|
2021
Q1 | $9.81M | Buy |
21,505
+2,893
| +16% | +$1.38M | 0.05% | 66 |
|
|
2020
Q4 | $8.67M | Buy |
18,612
+1,314
| +8% | +$616K | 0.05% | 64 |
|
|
2020
Q3 | $7.64M | Buy |
17,298
+786
| +5% | +$325K | 0.05% | 69 |
|
|
2020
Q2 | $5.98M | Buy |
16,512
+1,792
| +12% | +$601K | 0.05% | 74 |
|
|
2020
Q1 | $4.17M | Buy |
14,720
+3,259
| +28% | +$1.03M | 0.04% | 80 |
|
|
2019
Q4 | $3.72M | Buy |
11,461
+1,213
| +12% | +$368K | 0.03% | 104 |
|
|
2019
Q3 | $2.98M | Buy |
10,248
+635
| +7% | +$182K | 0.03% | 115 |
|
|
2019
Q2 | $2.82M | Buy |
9,613
+478
| +5% | +$132K | 0.02% | 116 |
|
|
2019
Q1 | $2.5M | Buy |
9,135
+1,902
| +26% | +$473K | 0.02% | 121 |
|
|
2018
Q4 | $1.62M | Buy |
+7,233
| New | +$1.7M | 0.02% | 157 |
|
Other funds holding TMO
Wealthfront Advisers's TMO Position: Q2 2026 in Review
Wealthfront Advisers reduced its Thermo Fisher Scientific (TMO) stake by 20% in Q2 2026, selling an estimated $3.09M and leaving 25,833 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #222.
Wealthfront Advisers first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. The position peaked at $23.5M in Q4 2021. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Wealthfront Advisers held 25,833 shares of Thermo Fisher Scientific worth $13M as of Q2 2026.
- Wealthfront Advisers sold 6,435 Thermo Fisher Scientific shares in Q2 2026, an estimated $3.09M.
- Thermo Fisher Scientific made up 0.02% of Wealthfront Advisers's portfolio in Q2 2026, its #222 holding.
- Wealthfront Advisers first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Thermo Fisher Scientific position peaked at $23.5M in Q4 2021.
- 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.